- Trials with a EudraCT protocol (2,819)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
2,819 result(s) found.
Displaying page 81 of 141.
EudraCT Number: 2015-003602-16 | Sponsor Protocol Number: PM1183-A-014-15 | Start Date*: 2022-02-24 | |||||||||||
Sponsor Name:Pharma Mar S.A. | |||||||||||||
Full Title: Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors. | |||||||||||||
Medical condition: Selected Advanced Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000923-37 | Sponsor Protocol Number: TriComB | Start Date*: 2021-08-04 | |||||||||||
Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST | |||||||||||||
Full Title: A phase 1/2 study exploring the safety and activity of Trifluridine/tipiracil in combination with capecitabine and bevacizumab in metastatic colorectal cancer patients. | |||||||||||||
Medical condition: metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017349-77 | Sponsor Protocol Number: TIGET-MLD | Start Date*: 2010-03-15 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: A Phase I/II clinical trial of hematopoietic stem cell gene therapy for the treatment of Metachromatic Leukodystrophy | |||||||||||||
Medical condition: metachromatic leukodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001320-19 | Sponsor Protocol Number: CTX001-121 | Start Date*: 2018-12-05 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sick... | |||||||||||||
Medical condition: Severe Sickle Cell Disease (SCD) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Completed) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000111-84 | Sponsor Protocol Number: ACE-LY-003 | Start Date*: 2020-02-04 | |||||||||||||||||||||
Sponsor Name:ACERTA PHARMA BV | |||||||||||||||||||||||
Full Title: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma | |||||||||||||||||||||||
Medical condition: B-cell Non-Hodgkin Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2024-000382-25 | Sponsor Protocol Number: SCY-078-120 | Start Date*: 2024-09-25 | |||||||||||
Sponsor Name:SCYNEXIS, Inc. | |||||||||||||
Full Title: A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Ibrexafungerp (SCY-078) in Adolescent Female Subjects | |||||||||||||
Medical condition: Vulvovaginal candidiasis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003592-42 | Sponsor Protocol Number: CLOFARABINE_UC | Start Date*: 2023-11-27 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Clofarabine Therapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: a Phase 1/2 Dose-Escalation Study | ||
Medical condition: Advanced urothelial carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001308-14 | Sponsor Protocol Number: PT-112-101 | Start Date*: 2023-02-27 | |||||||||||
Sponsor Name:Promontory Therapeutics Inc. | |||||||||||||
Full Title: A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Patients with Advanced Solid Tumors and Subsequent Expan... | |||||||||||||
Medical condition: metastatic Castration-Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003770-50 | Sponsor Protocol Number: 20200403 | Start Date*: 2021-10-13 | |||||||||||
Sponsor Name:Všeobecná fakultní nemocnice v Praze | |||||||||||||
Full Title: An Open-Label, Single/Multiple Ascending Dose Study to Assess the Pharmacokinetics, Efficacy, Safety and Tolerability of Inhalation Delivery of Hydroxychloroquine Sulfate (HCQ) in Healthy Volunteer... | |||||||||||||
Medical condition: Healthy volunteers and patients with COVID - 19 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001942-39 | Sponsor Protocol Number: EAE128 | Start Date*: 2022-10-24 | |||||||||||
Sponsor Name:Hellenic Society of Hematology (EAE) | |||||||||||||
Full Title: A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide, dexamethasone and nirogacestat... | |||||||||||||
Medical condition: Newly diagnosed patients with multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001941-19 | Sponsor Protocol Number: EAE127 | Start Date*: 2022-10-26 | |||||||||||
Sponsor Name:Hellenic Society of Hematology (EAE) | |||||||||||||
Full Title: A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE WITH OR WITHO... | |||||||||||||
Medical condition: Relapsed/refractory multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2024-000422-17 | Sponsor Protocol Number: C3671016 | Start Date*: 2024-08-26 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 1, OPEN-LABEL, AGE DESCENDING, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE (RSVpreF) IN CHILDREN ... | |||||||||||||
Medical condition: Prevention of RSV-associated lower respiratory tract illness in children 2-18 years of age by active immunization | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004102-63 | Sponsor Protocol Number: CNS-Lymphoma-Vorax-1 | Start Date*: 2021-05-07 |
Sponsor Name:Charité Universitätsmedizin Berlin | ||
Full Title: AN OPEN LABEL, PHASE I/II STUDY TO INVESTIGATE THE USE OF VORAXAZE™ AS INTENDED INTERVENTION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND WITH IMPAIRED RENAL FUNCTION BEING TREATED WITH HIG... | ||
Medical condition: CNS lymphoma (CNSL) being treated with HD-MTX in patients with impaired renal function | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001366-38 | Sponsor Protocol Number: CCTU0263 | Start Date*: 2022-10-13 | |||||||||||
Sponsor Name:Region Skåne – Skåne University Hospital | |||||||||||||
Full Title: STEM-PD trial: A multicentre, single arm, first in human, dose-escalation trial, investigating the safety and tolerability of intraputamenal transplantation of human embryonic stem cell derived dop... | |||||||||||||
Medical condition: Parkinson’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000547-24 | Sponsor Protocol Number: CCRG11-001 | Start Date*: 2012-02-27 | ||||||||||||||||
Sponsor Name:Antwerp University Hospital | ||||||||||||||||||
Full Title: Therapeutic efficacy of Wilms' tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with solid tumors: a phase I/feasibility study | ||||||||||||||||||
Medical condition: Therapeutic vaccination with dendritic cells loaded with Wilms' tumor 1 protein in patients with solid tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000714-33 | Sponsor Protocol Number: PT26/17/01 | Start Date*: 2023-02-21 | |||||||||||
Sponsor Name:tiakis Biotech AG (formerly Proteo Biotech AG) | |||||||||||||
Full Title: Efficacy and safety of Tiprelestat for treatment of severe COVID-19 (COMCOVID trial) | |||||||||||||
Medical condition: Adult patients with COVID-19 fulfilling the following criteria: -First laboratory-confirmation of the current episode of SARS-CoV-2 infection (COVID-19) as determined by PCR or antigen test (no sel... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001471-23 | Sponsor Protocol Number: UZBRU_VHH2_1 | Start Date*: 2019-02-06 |
Sponsor Name:UZ Brussel | ||
Full Title: Phase I/IIa study to evaluate the safety, biodistribution, radiation dosimetry and tumor imaging potential of 68GaNOTA-Anti-MMR-VHH2, a new radiopharmaceutical for in vivo imaging of Tumour-Associa... | ||
Medical condition: Tumour associated macrophages found in tumour lesions of two cancer types: breast cancer or melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005575-13 | Sponsor Protocol Number: CMV12/12 | Start Date*: 2013-05-16 | ||||||||||||||||||||||||||
Sponsor Name:Antwerp University Hospital | ||||||||||||||||||||||||||||
Full Title: Prophylactic vaccination with autologous dendritic cells against human cytomegalovirus: a pilot study in patients awaiting kidney transplantation | ||||||||||||||||||||||||||||
Medical condition: Cytomegalovirus infection in patients awaiting kidney transplantation and after kidney transplantation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002412-23 | Sponsor Protocol Number: DUO2022_01 | Start Date*: 2022-12-30 |
Sponsor Name:MB PHARMA s. r. o. | ||
Full Title: A prospective, randomized, double-blind, placebo-controlled Phase I/IIA Clinical Trial to demonstrate the safety and efficacy of DUOFAG® in bacterial infection treatment in patients with surgical w... | ||
Medical condition: Bacterial infection with Staphylococcus aureus and/or Pseudomonas aeruginosa in the surgical wound. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001693-33 | Sponsor Protocol Number: ITL-2002-CL-001 | Start Date*: 2022-03-30 | |||||||||||
Sponsor Name:Intellia Therapeutics, Inc. | |||||||||||||
Full Title: Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE) | |||||||||||||
Medical condition: Hereditary Angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
